Revenue growth and narrowing losses for the fiscal year ended February 2022
First written in FY2021. 2 of 6 entries say "Restated". Latest entry: FY2023-Q1.
No other company in this theme has enough history to compare yet.
- FY2023-Q1Cited as achievedAnnual report
「For the fiscal year ending February 2022, cash and cash equivalents at the end of the fiscal year increased from the end of the previous fiscal year, although operating cash flow was negative for the second consecutive fiscal year.」
The Company cites the previous fiscal year's revenue growth and narrower loss as past results in its explanation regarding the going-concern assumption. - FY2022AchievedAnnual report
「As a result, revenue for the current fiscal year was ¥2,119 million, up 4.0% from the previous fiscal year. In terms of earnings, the cost of sales decreased mainly because depreciation expenses declined, while selling, general and administrative expenses also decreased, primarily due to lower research and development expenses. Consequently, the operating loss narrowed to ¥378 million, compared with an operating loss of ¥596 million in the previous fiscal year.」
Against the revised outlook for the fiscal year ending February 2022 of revenue of ¥2,050 million and an operating loss of ¥460 million, actual revenue was ¥2,119 million and the operating loss was ¥378 million. Revenue exceeded the forecast and the operating loss narrowed. - FY2022-Q3RestatedAnnual report
「Based on progress during the six-month period ended in the second quarter of the fiscal year ending February 2022 and a review of the plan for the second half, the Company revised the full-year outlook for the fiscal year ending February 2022 announced on 12 April 2021. Revenue is projected at ¥2,050 million, ¥120 million below the initial plan. In terms of earnings, the Company expects ¥300 million in selling, general and administrative expenses, including research and development expenses, in the Innovation business, resulting in an operating loss of ¥460 million, ¥225 million below the initial plan, an ordinary loss of ¥465 million, ¥227 million below the initial plan, and a net loss of ¥360 million, ¥102 million below the initial plan.」
The full-year outlook for the fiscal year ending February 2022 revised in the second quarter, including revenue of ¥2,050 million and an operating loss of ¥460 million, remains unchanged. - FY2022-Q2SoftenedAnnual report
「Based on progress during the six-month period ended in the current second quarter and a review of the plan for the second half, the Company revised the full-year outlook for the fiscal year ending February 2022 announced on 12 April 2021. Revenue is now projected at ¥2,050 million, ¥120 million below the initial plan. In terms of earnings, the Company expects ¥300 million in selling, general and administrative expenses, including research and development expenses, in the Innovation business, resulting in an operating loss of ¥460 million, ¥225 million below the initial plan, an ordinary loss of ¥465 million, ¥227 million below the initial plan, and a net loss of ¥360 million, ¥102 million below the initial plan.」
The revenue target for the fiscal year ending February 2022 was revised down from ¥2,170 million to ¥2,050 million, while the projected operating loss was revised from ¥235 million to ¥460 million. - FY2022-Q1RestatedAnnual report
「The Company forecasts revenue of ¥2,170 million for the fiscal year ending February 2022, along with ¥300 million in selling, general and administrative expenses, including research and development expenses, in the Innovation business, an operating loss of ¥235 million, an ordinary loss of ¥238 million and a net loss of ¥258 million.」
The Company reiterates its outlook for the fiscal year ending February 2022: revenue of ¥2,170 million, selling, general and administrative expenses of ¥300 million, an operating loss of ¥235 million, an ordinary loss of ¥238 million and a net loss of ¥258 million. It also lists measures to strengthen the sales structure, manage research and development expenses and manage funds to increase revenue and reduce losses. - FY2021First statedAnnual report
「As a result, the outlook for the fiscal year ending February 2022 calls for revenue of ¥2,170 million, up 6.5% from the previous fiscal year. In terms of earnings, while reviewing spending and working to reduce costs, the Company plans to incur ¥300 million in selling, general and administrative expenses, including research and development expenses, in the Innovation business, resulting in a planned operating loss of ¥235 million, compared with an operating loss of ¥596 million in the previous fiscal year.」
For the fiscal year ending February 2022, the Company plans revenue of ¥2,170 million, up 6.5% year on year, and an operating loss of ¥235 million. It identifies spending reviews, cost reductions and management of research and development expenses as measures.